Therapy Areas: Respiratory
Kazia Therapeutics reports 100% clinical benefit rate in initial paxalisib breast cancer trial
28 August 2026 - Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company based in Sydney, Australia, announced on Thursday new data showing that its lead asset, paxalisi...
Oxcia receives EMA orphan designation for OXC-201 in idiopathic pulmonary fibrosis
27 August 2026 - Swedish clinical-stage biotech company Oxcia AB, which develops therapies targeting oxidative stress and DNA damage response pathways, announced on Thursday that the European Medicine...
Cizzle Bio presents CIZ1B biomarker blood test for lung cancer at Next Generation Dx Summit
27 August 2026 - Cizzle Bio Inc, a biotechnology company advancing biomarker blood tests for early cancer detection, announced on Wednesday its participation in the 18th Annual Next Generation Dx Summ...
Maverix Medical's Narwhal Cryo System receives FDA 510(k) clearance
21 August 2026 - Maverix Medical, a healthcare company focused on improving the diagnosis and treatment of lung cancer, announced on Thursday that the US Food and Drug Administration (FDA) granted 510...
Pillar Biosciences, LC-SCRUM-Asia and LSI Medience collaborate for liquid biopsy screening in lung cancer
20 August 2026 - US-based biotechnology company Pillar Biosciences Inc announced on Wednesday a collaboration with LC-SCRUM-Asia, a lung cancer screening project, and LSI Medience Corporation, a Japan...
Vascarta commences NIH phase I clinical study of VAS-101 in sickle cell disease
20 August 2026 - Pharmaceutical company Vascarta Inc announced on Wednesday that a second proof of concept phase I clinical study of VAS-101 (Vasceptor; topical curcumin gel) in sickle cell disease (S...